INSP stock forecast, quote, news & analysis
Inspire Medical Systems Inc operates as a medical technology company... Show more
Why Inspire Medical Systems (INSP) Stock Is Up +11% in the Last 30 Days
Key Takeaways
- Inspire Medical Systems (INSP) shares climbed roughly 11% over the trailing 30 days, moving from about $61.80 to near $68.66.
- The advance extends a broader recovery, with the stock up more than 50% over the trailing three months after a difficult first half of the year.
- Investor confidence has been supported by a second-quarter earnings beat, raised 2026 guidance, and the new Project Horizon growth initiative.
- Analyst upgrades and proposed 2027 CMS reimbursement increases for the Inspire V procedure reinforced the positive tone.
- Coding and reimbursement disruptions, along with emerging competition, remain the primary risks to monitor.
Inspire Medical Systems (INSP) Company Overview and Market Position
Inspire Medical Systems is a medical technology company focused on developing and commercializing minimally invasive neurostimulation treatments for moderate to severe obstructive sleep apnea (OSA). Its proprietary Inspire therapy — the first FDA-approved hypoglossal nerve stimulation technology for this indication — delivers mild stimulation to keep the airway open during sleep for patients who cannot tolerate or do not benefit from CPAP therapy.
The company's current-generation Inspire V system integrates a respiratory sensor into the neurostimulator, simplifying the implant procedure. Inspire sells directly to hospitals and ambulatory surgery centers across the United States, as well as in select European markets and Japan, and has treated more than 140,000 patients since inception. The company holds a first-mover position in the hypoglossal nerve stimulation segment, though competition is expanding from players such as LivaNova (LIVN) and Nyxoah (NYXH).
Inspire Medical Systems (INSP) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, INSP advanced approximately 11%, from a closing level near $61.80 to about $68.66. The stock reached an intraday high near $78.80 in mid-September before consolidating as some investors took profits.
The move is part of a larger recovery. Over the trailing three months, INSP has climbed more than 50% from roughly $43 in late June, reversing much of the decline seen earlier in the year, when the stock fell sharply after the company reduced its 2026 outlook.
What Drove INSP Stock Price in the Last 30 Days
The recent 30-day advance largely reflects continued positive sentiment following the company's second-quarter results reported in early August. Inspire delivered a "beat and raise" quarter — revenue of $200.6 million and adjusted earnings of $0.14 per share both topped consensus estimates — and raised its full-year 2026 guidance for revenue, adjusted operating margin, and adjusted earnings.
That momentum was reinforced by a series of analyst actions. Oppenheimer upgraded the stock to Outperform with an $85 price target, while firms including RBC, Baird, and Piper Sandler raised their price targets. Investors also responded to CMS's proposed 2027 reimbursement increases for the Inspire V procedure — a 12% rise for hospital outpatient settings and a 15% increase for ambulatory surgery centers — which were viewed as a sign of improving reimbursement clarity.
What Drove INSP Stock Performance Over the Last Quarter
The three-month trend reflects a broader shift in sentiment. Earlier in 2026, coding and reimbursement disruptions tied to the phase-out of a key CPT code and the WISeR program slowed U.S. procedure activity and prompted the company to cut its 2026 outlook, pressuring the stock.
The narrative began to turn in June, when Inspire presented full Inspire V trial results and cardiovascular-outcome data at the American Academy of Sleep Medicine conference. The inflection point arrived in early August, when second-quarter results beat expectations and management raised guidance while launching Project Horizon, a restructuring plan expected to create about $30 million in annualized growth investment capacity. The stock jumped roughly 18% in a single session following the report and continued to climb through September.
Trending AI Robots
Tickeron's Trending AI Robots page offers a curated view of the platform's top-performing and most relevant AI trading bots. While Tickeron provides hundreds of AI-driven trading bots that collectively trade thousands of tickers, only those demonstrating standout performance and relevance appear in this featured section. The bots vary widely in strategy, timeframe, and performance metrics, giving users the ability to explore different approaches to automated trading. For those interested in systematic, data-driven trading strategies, the Trending AI Robots page serves as a useful starting point.
INSP Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor several factors in the months ahead. Third-quarter results will test whether the company can deliver the sequential improvement management has guided toward, with third-quarter revenue expected to decline 8% to 10% year over year. Final 2027 CMS reimbursement rates, expected in November, will determine whether the proposed facility-rate increases are confirmed.
The company's revised application for a new Category 1 CPT code — targeting implementation on January 1, 2028 — remains a key long-term catalyst for coding clarity. Execution of Project Horizon, including its restructuring charges, and the pace of prior-authorization improvement will also be closely watched. Finally, competition from LivaNova's (LIVN) recently approved aura6000 system and Nyxoah's (NYXH) Genio platform could shape market-share dynamics.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
INSP in -4.78% downward trend, sliding for three consecutive days on October 14, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where INSP declined for three days, in 249 of 319 cases, the price declined further within the following month. The odds of a continued downward trend are 78%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for INSP moved out of overbought territory on September 22, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 20 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 67%.
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on INSP as a result. In 64 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 76%.
The Moving Average Convergence Divergence Histogram (MACD) for INSP turned negative on September 23, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 33 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 75%.
INSP broke above its upper Bollinger Band on September 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 45 of 59 cases where INSP's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The 50-day moving average for INSP moved above the 200-day moving average on September 30, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +7.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where INSP advanced for three days, in 231 of 282 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
The Aroon Indicator entered an Uptrend today. In 146 of 199 cases where INSP Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. INSP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 50 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 57 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.451) is normal, around the industry mean (10.930). P/E Ratio (15.453) is within average values for comparable stocks, (100.178). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (2.375) is also within normal values, averaging (40.124).
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INSP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of implantable neurostimulation systems to treat obstructive sleep apnea
Industry MedicalNursingServices